Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

Chiara Bernelli; Georgina Fuertes Ferre; Alaide Chieffo

doi:10.1586/erc.12.183

Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

Chiara Bernelli, Georgina Fuertes Ferre, Alaide Chieffo

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

Original language	English
Pages (from-to)	151-154
Number of pages	4
Journal	Expert Review of Cardiovascular Therapy
Volume	11
Issue number	2
DOIs	https://doi.org/10.1586/erc.12.183
Publication status	Published - Feb 2013

Keywords

diabetes mellitus
drug-eluting stents
major adverse cardiac events
percutaneous coronary intervention

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Internal Medicine

Access to Document

10.1586/erc.12.183

Fingerprint Dive into the research topics of 'Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial'. Together they form a unique fingerprint.

Cite this

@article{b15cbff7a1634599a5f28319633ab846,

title = "Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial",

abstract = "Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.",

keywords = "diabetes mellitus, drug-eluting stents, major adverse cardiac events, percutaneous coronary intervention",

author = "Chiara Bernelli and Ferre, {Georgina Fuertes} and Alaide Chieffo",

year = "2013",

month = feb,

doi = "10.1586/erc.12.183",

language = "English",

volume = "11",

pages = "151--154",

journal = "Expert Review of Cardiovascular Therapy",

issn = "1477-9072",

publisher = "Expert Reviews Ltd.",

number = "2",

}

TY - JOUR

T1 - Diabetes and everolimus-eluting stents

T2 - What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

AU - Bernelli, Chiara

AU - Ferre, Georgina Fuertes

AU - Chieffo, Alaide

PY - 2013/2

Y1 - 2013/2

N2 - Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

AB - Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

KW - diabetes mellitus

KW - drug-eluting stents

KW - major adverse cardiac events

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84873892250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873892250&partnerID=8YFLogxK

U2 - 10.1586/erc.12.183

DO - 10.1586/erc.12.183

M3 - Article

C2 - 23405836

AN - SCOPUS:84873892250

VL - 11

SP - 151

EP - 154

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 2

ER -

Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this